Bozeman, MT (June 24, 2008) – Golden Helix, Inc., the global leader in genetic association software, today announced that GlaxoSmithKline has renewed a worldwide site license for HelixTree®, the company’s flagship genetic analysis product and cornerstone application of Golden Helix’s SNP & Variation Suite.
HelixTree employs advanced statistical methodologies for candidate gene and whole genome association studies designed to elucidate complex relationships among genetic, environmental, and clinical data. The software was originally developed in 1998 in collaboration with GlaxoSmithKline where it has since been instrumental in advancing pharmacogenetic initiatives.
About Golden Helix
Founded in 1998, Golden Helix has become the global leader in SNP analysis and genetic association software. The company's products are used by hundreds of researchers at the world's top pharmaceutical, biotech and non-profit research organizations, and have been cited in over 100 peer reviewed publications that detail ground-breaking research uncovering the genetic and environmental basis of disease. Golden Helix is committed to Accelerating the Quest for Significance. For more information, please visit www.goldenhelix.com.
Director of Marketing
Golden Helix, Inc.